BioSpring.Ltd – Healing Beyond Borders
  • Home
  • About Us
  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • Manufacturing
  • Product Verify
  • Contact Us
  • Home
  • About Us
  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • Manufacturing
  • Product Verify
  • Contact Us
Product Pipeline
  • All Categories
  • Our Focus
    • Product Pipeline
    • Global Market
    • Press Release
Tag
  • All Tags
  • PRnews
  • Generic Drug
Order By
  • Default
  • Order By Date
  • Order By Title
  • Order By ID
  • BioSpring Launches BIOMOB to treat EGFR Ex20ins mutated lung cancer for Global Market Clients

    BioSpring Launches BIOMOB to treat EGFR Ex20ins mutated lung cancer for Global Market Clients

    Product Pipeline 11.07.2022 115 Views

    November 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOMOB (Mobocertinib 40mg) capsules for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutation. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.Mobocertinib is an irreversible kinase inhibitor, forming a covalent…

  • BioSpring Launches Oral Psoriasis Therapy BIODEUCRA for Global Market Clients

    BioSpring Launches Oral Psoriasis Therapy BIODEUCRA for Global Market Clients

    Product Pipeline 10.06.2022 363 Views

    October 06, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIODEUCRA (Deucravacitinib 6mg) tablets for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the first approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis…

  • BioSpring launches BIOPALB for HR+/HER2- mBC breast cancer in global market

    BioSpring launches BIOPALB for HR+/HER2- mBC breast cancer in global market

    Product Pipeline 10.05.2022 185 Views

    October 05, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOPALB (Palbociclib 125mg) capsules are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or fulvestrant in patients…

  • BioSpring launches Bioscovy for PrEP in global market

    BioSpring launches Bioscovy for PrEP in global market

    Product Pipeline 09.20.2022 166 Views

    September 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Bioscovy (emtricitabine 200mg/ tenofovir alafenamide 25mg) tablet for customers, each box of Bioscovy includes 30 tablets. It is a tablet taken by mouth.  Bioscovy for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. Bioscovy for PrEP is not for everyone: It is not…

BioSpring.Ltd – Healing Beyond Borders

Our world-class finished dose manufacturing facility is located in the middle of the best industrial development areas in Laos [Saysetteha Development Zone]. The factory has specialized manufacturing modules for oral solid dose tablets, capsules, injections and caters to both export and domestic markets.

  • Our Focus
    • Press Release
    • Global Market
    • Product Pipeline
  • About Us
    • Manufacturing
    • Product Verify
    • Contact Us

Follow Us

  • LienTeh
  • Eeinpresswire

Copyright © 2022. BioSpring.LTD. All rights reserved.

Privacy Policy Terms & Conditions